Table 2 Spirometry results of study participants at week 8, 26 and 52 after TB treatment initiation, included in final analysis (N = 62)

% of N

100.00

77.97

22.03

100.00

68.85

31.15

100.00

64.52

35.48

FVC in l (SD)

2.79 (0.76)

2.56 (0.60)

3.61 (0.70)

2.91 (0.79)

2.57 (0.60)

3.66 (0.62)

3.05 (0.78)

2.66 (0.58)

3.77 (0.55)

FVC in % of pred. (SD)

69.00 (15.18)

63.68 (11.84)

87.85 (9.75)

72.00 (15.46)

64.27 (11.05)

89.09 (8.41)

75.46 (14.96)

67.48 (11.21)

89.99 (8.62)

FVC z-score (SD)^a

−2.52 (1.30)

−2.96 (1.06)

−0.98 (0.78)

−2.25 (1.24)

− 2.88 (0.88)

− 0.87 (0.66)

−1.99 (1.21)

−2.64 (0.90)

− 0.80 (0.68)

FEV1 in l (SD)

2.27 (0.68)

2.06 (0.54)

3.01 (0.64)

2.33 (0.70)

2.02 (0.52)

3.01 (0.54)

2.44 (0.70)

2.09 (0.52)

3.07 (0.52)

FEV1 in % of pred. (SD)

69.54 (16.64)

63.54 (12.81)

90.76 (9.86)

71.39 (17.72)

62.60 (13.06)

90.82 (8.96)

74.82 (16.63)

66.28 (12.89)

90.35 (10.15)

FEV1 z-score (SD)^a

−2.26 (1.28)

−2.71 (1.02)

−0.68 (0.76)

−2.10 (1.27)

− 2.74 (0.90)

− 0.68 (0.67)

−1.85 (1.21)

−2.47 (0.93)

−0.72 (0.74)

Ratio (FEV1/FVC)

81.14 (9.74)

80.66 (10.69)

82.85 (5.11)

79.31 (8.69)

78.01 (9.55)

82.17 (5.64)

79.44 (7.95)

78.50 (9.28)

81.16 (4.31)

FEV1/FVC z-score (SD)^a

−0.42 (1.59)

−0.49 (1.75)

− 0.17 (0.74)

−0.77 (1.22)

− 0.98 (1.33)

−0.31 (0.79)

− 0.75 (1.28)

−0.92 (1.50)

− 0.46 (0.69)